Drug intelligence / Profile preview

TBC-190

Development stage: Unknown
Lead developer: FibroBiologics
Modality: Adoptive Cell Transfer → Cell Therapies

Overview

TBC-190 is an investigational immune cell therapy developed by FibroBiologics. It is currently in the discovery phase and is being explored for its potential to reverse thymic involution, restore thymus function, and suppress the impact of aging on the immune system. The primary therapeutic area under investigation is immune system diseases, with a focus on regenerative medicine approaches to rejuvenate or enhance immune function[1][2].

Beyond the preview

Go deeper on TBC-190.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBC-190.

Explore the full profile